A study of denileukin diftitox to treat refractory ovarian cancer.

Cheryl Czerlanis,Maureen Drakes,Amira Elmishad,Kelly Kosik,Mala Parthasarathy,Ronald K. Potkul,Donna Marie Smith,Zheng Yu,Sandra Zakrzewski,Patrick J. Stiff

A study of denileukin diftitox to treat refractory ovarian cancer.

2017

Cheryl Czerlanis
Maureen Drakes
Amira Elmishad
Kelly Kosik
Mala Parthasarathy
Ronald K. Potkul
Donna Marie Smith
Zheng Yu
Sandra Zakrzewski
Patrick J. Stiff

e13121 Background: The number of circulating CD4+ regulatory T-cells (Tregs) has been correlated with outcome in advanced ovarian cancer. A prior report (Barnett, et al; AACR Abstracts 2006: 1148) ...

Keywords:

Denileukin diftitox
Pathology
Oncology
Internal medicine
Ovarian cancer
Refractory
Medicine
advanced ovarian cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations